View Older Stories View More Recent Stories

Jul 1, 2019 07:30AM Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients
Jul 1, 2019 07:30AM Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients
Jul 1, 2019 07:30AM Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients
Jun 26, 2019 07:00AM Akcea and Ionis Announce Upcoming Data Presentations at the 5th European Academy of Neurology Annual Congress
Jun 26, 2019 07:00AM Akcea and Ionis Announce Upcoming Data Presentations at the 5th European Academy of Neurology Annual Congress
Jun 20, 2019 04:38PM Akcea and Ionis Announce Upcoming Data Presentations at the 2019 Peripheral Nerve Society Annual Meeting
Jun 20, 2019 04:38PM Akcea and Ionis Announce Upcoming Data Presentations at the 2019 Peripheral Nerve Society Annual Meeting
Jun 18, 2019 07:05AM Ionis Pharmaceuticals to present at the BMO Prescription for Success Healthcare Conference
Jun 12, 2019 04:05PM Ionis announces appointment of Joan E. Herman to its board of directors
Jun 6, 2019 07:05AM Ionis Pharmaceuticals to provide corporate update and 30-year retrospective at its 2019 Annual Meeting of Stockholders
May 28, 2019 07:00AM Akcea Therapeutics to Present at Upcoming Investor Conferences
May 28, 2019 07:00AM Akcea Therapeutics to Present at Upcoming Investor Conferences
May 15, 2019 06:02AM Biogen (BIIB) Reports Positive Recommendation for SPINRAZA (nusinersen) from NICE for Funding with U.K.'s National Health Service
May 14, 2019 07:02PM Biogen’s SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy
May 14, 2019 07:02PM Biogen’s SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy
May 9, 2019 07:00AM Ionis reports first quarter 2019 financial results
May 8, 2019 04:05PM Akcea Reports Financial Results and Highlights for First Quarter 2019
May 8, 2019 04:05PM Akcea Reports Financial Results and Highlights for First Quarter 2019
May 7, 2019 04:05PM New Long-Term TEGSEDI Safety and Efficacy Data Featured as an Oral Presentation at 2019 American Academy of Neurology Annual Meeting (AAN)
May 7, 2019 04:05PM New Long-Term TEGSEDI Safety and Efficacy Data Featured as an Oral Presentation at 2019 American Academy of Neurology Annual Meeting (AAN)
May 7, 2019 08:43AM Akcea Therapeutics (AKCA), Ionis (IONS) Announce Approval of WAYLIVRA in European Union
May 7, 2019 08:41AM Akcea and Ionis Announce Approval of WAYLIVRA® (volanesorsen) in the European Union
May 7, 2019 08:41AM Akcea and Ionis Announce Approval of WAYLIVRA® (volanesorsen) in the European Union
May 6, 2019 07:30AM Biogen Presents Data at 2019 AAN Annual Meeting Affirming Longer-Term Safety and Durability of Treatment with SPINRAZA® (nusinersen)
May 6, 2019 07:05AM Ionis launches new corporate brand that reflects company's industry-leading innovation and unique culture of saying "yes" to patients
May 2, 2019 07:05AM Akcea Announces Upcoming Data Presentations at the 2019 American Academy of Neurology Meeting (AAN.19)
May 2, 2019 07:05AM Akcea Announces Upcoming Data Presentations at the 2019 American Academy of Neurology Meeting (AAN.19)
May 1, 2019 07:30AM Biogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases
May 1, 2019 07:05AM Positive clinical data at AAN 2019 reinforces Ionis' commitment to delivering life-changing medicines to patients with neurological diseases
Apr 30, 2019 07:45AM Biogen (BIIB) Reports Data Publication in Neurology Showing that Treatment with SPINRAZA (nusinersen) Improved Motor Function, Provided Long-Term Benefit
Apr 30, 2019 07:33AM Data Published in Neurology Show that Treatment with SPINRAZA® (nusinersen) Improved Motor Function and Provided Long-Term Benefit for Individuals with Later-Onset Spinal Muscular Atrophy
Apr 25, 2019 07:05AM Ionis Pharmaceuticals to hold first quarter 2019 financial results webcast
Apr 24, 2019 07:00AM Akcea Therapeutics to Hold First Quarter 2019 Financial Results Webcast
Apr 24, 2019 07:00AM Akcea Therapeutics to Hold First Quarter 2019 Financial Results Webcast
Apr 12, 2019 07:30AM Biogen Continues to Advance Innovation in SMA with New Data in Adults and Infants to Be Presented at MDA Clinical and Scientific Conference
Apr 8, 2019 04:05PM Ionis Pharmaceuticals to Provide Corporate Update at 2019 Annual Meeting of Stockholders
Mar 25, 2019 07:32AM Ionis Pharmaceuticals (IONS) Announces Brett P. Monia Ph.D. to Board
Mar 25, 2019 07:05AM Ionis announces appointment of Brett P. Monia Ph.D. to its board of directors
Mar 15, 2019 04:06PM Akcea Therapeutics (AKCA), Ionis (IONS) Announce Upcoming Data Presentations at ACC.19
Mar 15, 2019 04:05PM Akcea and Ionis Announce Upcoming Data Presentations at the 2019 American College of Cardiology Meeting (ACC.19)
Mar 15, 2019 04:05PM Akcea and Ionis Announce Upcoming Data Presentations at the 2019 American College of Cardiology Meeting (ACC.19)
Mar 7, 2019 07:05AM Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
Mar 1, 2019 07:48AM Ionis Pharmaceuticals Inc. (IONS), Akcea Therapeutics (AKCA) Report Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen)
Mar 1, 2019 07:45AM Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen)
Mar 1, 2019 07:45AM Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen)
Feb 28, 2019 07:30AM Biogen Further Expands Presence in China with Approval of SPINRAZA® (nusinersen), the First and Only Treatment for Spinal Muscular Atrophy
Feb 28, 2019 07:00AM Akcea® Recognizes Rare Disease Day Through Efforts to Increase Awareness of Hereditary Transthyretin Amyloidosis and Familial Chylomicronemia Syndrome
Feb 27, 2019 07:00AM Ionis Exceeds 2018 Financial Guidance
Feb 26, 2019 04:05PM Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2018
Feb 25, 2019 01:15AM AKCEA-APO(a)-LRx Advances as Leading Pharmaceutical Company Exercises Option to License
View More Recent Stories View Older Stories